AGIO Agios Pharmaceuticals Inc.

Agios to Webcast Conference Call of Fourth Quarter and Year End 2020 Financial Results on February 25, 2021

Agios to Webcast Conference Call of Fourth Quarter and Year End 2020 Financial Results on February 25, 2021

CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that the company will host a conference call and live webcast on Thursday, February 25, 2021 at 8:00 a.m. ET to report its fourth quarter and year end 2020 financial results and other business highlights.

A live webcast can be accessed under "Events & Presentations" in the Investors section of the company's website at . The conference call can be accessed by dialing 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and referring to conference ID 8442238. The webcast will be archived and made available for replay on the company's website beginning approximately two hours after the event.

About Agios

Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and genetically defined diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across these three therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development. For more information, please visit the company's website at .

Contacts

Investors:

Holly Manning, 617-844-6630

Director, Investor Relations

 

Media:

Jessica Rennekamp, 857-209-3286

Associate Director, Corporate Communications

 

 



EN
11/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agios Pharmaceuticals Inc.

 PRESS RELEASE

Agios to Webcast Conference Call of First Quarter 2024 Financial Resul...

Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024 CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 2, 2024, at 8:00 a.m. ET to report its first quarter 2024 financial results and other business highlights. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company'...

 PRESS RELEASE

Agios Publishes 2024 Environmental, Social and Governance (ESG) Report

Agios Publishes 2024 Environmental, Social and Governance (ESG) Report – Report Highlights Company’s Focus on Red Blood Cell Health; Diversity, Equity & Inclusion; and Strong Corporate Governance – – Aligns with the Sustainability Accounting Standards Board (SASB) Standards for the Biotechnology and Pharmaceuticals Industry and the United Nations Sustainable Development Goals (UN SDGs) – CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced...

Agios Pharmaceuticals Inc: 2 directors

Two Directors at Agios Pharmaceuticals Inc sold/sold after exercising options 6,628 shares at between 31.750USD and 32.004USD. The significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades b...

 PRESS RELEASE

Agios to Present at the Leerink Partners Global Biopharma Conference o...

Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024 CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024, at 10:00 a.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at . A replay of the webcast will...

 PRESS RELEASE

Agios to Present at the TD Cowen 44th Annual Health Care Conference on...

Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024 CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the TD Cowen 44th Annual Health Care Conference on Monday, March 4, 2024, at 2:10 p.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at . A replay of the webcast will be archived...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch